Synergistic effect of recombinant IL 2 and interferon-gamma on the proliferation of human monoclonal lymphocytes.
We studied the effect of interferon-gamma (IFN-gamma) on the proliferation of lymphocytes from 10 B-type chronic lymphocytic leukemia (B-CLL) patients. In no instance did IFN-gamma induce a proliferative response whether used alone or in combination with anti-mu antibody (Ab). This was observed regardless of the responsiveness of a given patient's cells to interleukin 2 (IL 2) and to B cell growth factor (BCGF). In contrast IFN-gamma strongly and reproducibly synergized with IL 2 (but not with BCGF) to support B-CLL proliferation in five of the 10 patients. The effect of IFN-gamma was dose related and could be inhibited by an anti-IFN-gamma monoclonal Ab. A monoclonal Ab toward the IL 2 receptor molecule was also inhibitory. Preincubation with IFN-gamma potentiated the responsiveness of B-CLL to IL 2 in secondary cultures, showing that IFN-gamma exerts its effect before that of IL 2.
D001402:B-Lymphocytes / Q000502:physiology*; D002999:Clone Cells / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000008:administration & dosage*; D015847:Interleukin-4; D007700:Kinetics; D007945:Leukemia, Lymphoid / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects; D008222:Lymphokines / Q000494:pharmacology; D011994:Recombinant Proteins
D006133:Growth Substances; D007376:Interleukin-2; D008222:Lymphokines; D011994:Recombinant Proteins; D015847:Interleukin-4; D007371:Interferon-gamma